Menu

Image of the Day: Nose Dive

Numbers of avian species in the Mojave Desert have fallen.

Aug 7, 2018
Sukanya Charuchandra

ABOVE: An adult sage thrasher (Oreoscoptes montanus) perches on a bush in the Mojave Desert.
CHELSEA HOFMEIER 

Researchers surveyed the Mojave Desert in the US to assess the impact of climate change on birds and recorded a 43 percent drop in the number of species that make their homes there. The findings, published yesterday (August 6) in PNAS, include observations from 61 sites that were previously studied in the early 20th century. The collapse of avian species numbers has been linked to lower precipitation, with greater species diversity found in areas with surface water. 

K.J. Iknayan and S.R. Beissinger, “Collapse of a desert bird community over the past century driven by climate change,” PNAS, doi:10.1073/pnas.1805123115, 2018.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.